Neuropsychiatrie features of dementia with lewy bodies

Dementia with Lewy Bodies: and Parkinson's Disease Dementia

Volumn , Issue , 2005, Pages 73-94

  Apostolova, Liana G ^a   Cummings, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960843976     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (132)

1. Aarsland D, Tandberg E, Larsen JP, Cummings JL, Frequency of dementia in Parkinson disease. Arch Neurol (1996) 53:538-42.
2. Aarsland D, Larsen JP, Cummings JL, Laake K, Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol, (1999a) 56:595-601.
3. Aarsland D, Larsen JP, Lim NG et al, Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry (1999b) 67:492-6.
4. Aarsland D, Andersen K, Larsen JP et al, Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology (2001a) 56:730-6.
5. Aarsland D, Ballard C, Larsen JP, McKeith I, A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J Geriatr Psychiatry (2001b) 16:528-36.
6. Aarsland D, Laake K, Larsen JP, Janvin C, Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry (2002) 72:708-12.
7. Albin RL, Minoshima S, D’Amato CJ et al, Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology (1996) 47:462-6.
8. Allen RL, Walker Z, D’Ath PJ, Katona CL, Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet (1995) 346:185.
9. Arnulf I, Bonnet AM, Damier P et al, Hallucinations, REM sleep and Parkinson’s disease: a medical hypothesis. Neurology (2000) 55:281-8.
10. Ball K, Owsley C, The useful field of view test: a new technique for evaluating age-related declines in visual function. J Am Optom Assoc (1993) 64:71-9.
11. Ballard C, Lowery K, Harrison R, McKeith IG, Noncognitive symptoms in Lewy body dementia. In: Perry RH, McKeith IG, Perry EK, eds, Dementia with Lewy Bodies (1st edn) (Cambridge University Press: Cambridge, UK, 1996) 67-84.
12. Ballard C, O’Brien J, Coope B et al, A prospective study of psychotic symptoms in dementia sufferers: psychosis in dementia. Int Psychogeriatr (1997a) 9:57-64.
13. Ballard C, McKeith I, Harrison R et al, A detailed phenomenological comparison of complex visual hallucinations in dementia with Lewy bodies and Alzheimer’s disease. Int Psychogeriatr (1997b) 9:381-8.
14. Ballard CG, O’Brien J, Lowery K et al, A prospective study of dementia with Lewy bodies. Age Ageing (1998) 27:631-6.
15. Ballard C, Holmes C, McKeith I et al, Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiatry (1999) 156:1039-45.
16. Ballard C, Piggott M, Johnson M et al, Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol (2000) 48:868-76.
17. Ballard CG, O’Brien JT, Swann AG et al, The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer’s disease: persistence and new cases over 1 year of follow-up. J Clin Psychiatry (2001) 62:46-9.
18. Boeve BF, Silber MH, Ferman TJ et al, REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology (1998) 51:363-70.
19. Boeve BF, Silber MH, Ferman TJ et al, Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord (2001) 16:622-30.
20. Boeve BF, Silber MH, Parisi JE et al, Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology (2003a) 6:40-5.
21. Boeve BF, Silber MH, Ferman TJ, Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med (2003b) 4:281-4.
22. Boeve BF, Ferman TJ, Silber MH et al, Sleep disturbances in dementia with Lewy bodies involve more than REM sleep behavior disorder. Presented at the 55th Annual meeting of the American Academy of Neurology, Honolulu, HI (2003c).
23. Burke WJ, Pfeiffer RF, McComb RD, Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci (1998) 10:227-9.
24. Burkhardt CR, Filley CM, Kleinschmidt-DeMasters BK et al, Diffuse Lewy body disease and progressive dementia. Neurology (1988) 38:1520-8.
25. Byrne EJ, Lennox G, Lowe J, Godwin-Austen RB, Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry (1989) 52:709-17.
26. Cercy SP, Bylsma FW, Lewy bodies and progressive dementia: a critical review and meta-analysis. J Int Neuropsychol Soc (1997) 3:179-94.
27. Chacko RC, Hurley RA, Jankovic J, Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci (1993) 5:206-8.
28. Cheng AV, Ferrier IN, Morris CM et al, Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer’s and Parkinson’s diseases. J Neurol Sei (1991) 106:50-5.
29. Collerton D, Burn D, McKeith I, O’Brien J, Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord (2003) 16:229-37.
30. Colloby SJ, Fen wick JD, Williams ED et al, A comparison of 99mTc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer’s disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging (2002) 29:615-22.
31. Court JA, Ballard CG, Piggott MA et al, Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies. Pharmacol Biochem Behav (2001) 70:571-9.
32. Cummings JL, The dementias of Parkinson’s disease: prevalence, characteristics, neurobiology, and comparison with dementia of the Alzheimer type. Eur Neurol (1988) 28(Suppl l):15-23.
33. Cummings JL, Depression and Parkinson’s disease: a review. Am J Psychiatry (1992) 149: 443-54.
34. Cummings JL, The Neuropsychiatry of Alzheimer’s Disease and Related Dementias (1st edn) (Martin Dunitz: London, 2003).
35. Cummings JL, Back C, The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer’s disease. Am J Geriatr Psychiatry (1998) 6:S64-S78.
36. Cummings JL, Gorman DG, Shapira J, Physostigmine ameliorates the delusions of Alzheimer’s disease. Biol Psychiatry (1993) 33:536-41.
37. Cummings JL, Mega M, Gray K et al, The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology (1994) 44: 2308-14.
38. Cummings JL, Street J, Masterman D, Clark WS, Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dement Geriatr Cogn Disord (2002) 13:67-73.
39. Davis P, Baskys A, Quetiapine effectively reduces psychotic symptoms in patients with Lewy body dementia: an advantage of the unique pharmacological profile? Brain Aging (2002) 2:49-53.
40. Del Ser T, McKeith I, Anand R et al, Dementia with Lewy bodies: findings from an international multicentre study. Int J Geriatr Psychiatry (2000) 15:1034-45.
41. Del Ser T, Hachinski V, Merskey H, Munoz DG, Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord (2001) 15:31-44.
42. DSM-IV TR, Diagnostic and Statistical Manual of Mental Disorders (4th edn), Text Revision (American Psychiatric Association: Washington DC, 2000).
43. Diederich NJ, Goetz CG, Raman R et al, Poor visual discrimination and visual hallucinations in Parkinson’s disease. Clin Neuropharmacol (1998) 21:289-95.
44. Donnemiller E, Heilmann J, Wenning GK, et al, Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 12:iI-B-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med (1997) 24:320-5.
45. Edwards KR, Hershey L, Wray L et al, Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriatr Cogn Disord (2004) 17(Suppl l):40-8.
46. Fenelon G, Mahieux F, Huon R, Ziegler M, Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain (2000) 123:733-45.
47. Ferman TJ, Boeve BF, Smith GE et al, REM sleep behavior disorder and dementia: cognitive differences when compared with AD. Neurology (1999) 52:951-7.
48. Ferman TJ, Boeve BF, Smith GE et al, Dementia with Lewy bodies may present as dementia and REM sleep behavior disorder without parkinsonism or hallucinations. J Int Neuropsychol Soc (2002) 8:907-14.
49. Fetoni V, Soliveri P, Monza D et al, Affective symptoms in multiple system atrophy and Parkinson’s disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry (1999) 66:541-4.
50. Forstl H, Burns A, Jacoby R, Levy R, Neuroanatomical correlates of clinical misidentifi-cation and misperception in senile dementia of the Alzheimer type. J Clin Psychiatry (1991) 52:268-71.
51. Goetz CG, Stebbins GT Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology (1995) 45:669-71.
52. Gomez-Tortosa E, Ingraham AO, Irizarry MC, Hyman BT, Dementia with Lewy bodies. J Am Geriatr Soc (1998) 46:1449-58.
53. Grace J, Daniel S, Stevens T, Shankar KK et al, Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatrics (2001) 13:199-205.
54. Hansen L, Salmon D, Galasko D et al, The Lewy body variant of Alzheimer’s disease: a clinical and pathological entity. Neurology (1990) 40:1-8.
55. Harding AJ, Halliday GM, Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) (2001) 102:355-63.
56. Harding AJ, Broe GA, Halliday GM, Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain (2002) 125:391-403.
57. Hayflick SJ, Westaway SK, Levinson B et al, Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med (2003) 348:33-40.
58. Hirono N, Mori E, Tanimukai S et al, Distinctive neurobehavioral features among neurodegenerative dementias. J Neuropsychiatry Clin Neurosci (1999) 11: 498-503.
59. Holroyd S, Shepherd ML, Downs JH 3rd, Occipital atrophy is associated with visual hallucinations in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci (2000) 12:25-8.
60. Holroyd S, Currie L, Wooten GF, Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry (2001) 70:734-8.
61. Hughes TA, Ross HF, Musa S et al, A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology (2000) 54:1596-602.
62. Hurtig HI, Trojanowski JQ, Galvin J et al, Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology (2000) 54:1916-21.
63. Hutchinson M, Fazzini E, Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry (1996) 61: 324-5.
64. Imamura T, Ishii K, Sasaki M et al, Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease: a comparative study using positron emission tomography. Neurosci Lett (1997) 235:49-52.
65. Imamura T, Ishii K, Hirono N et al, Visual hallucinations and regional cerebral metabolism in dementia with Lewy bodies (DLB). Neuroreport (1999) 10:1903-7.
66. Imamura T, Ishii K, Hirono N et al, Occipital glucose metabolism in dementia with Lewy bodies with and without Parkinsonism: a study using positron emision tomography. Dement Geriatr Cogn Disord (2001) 12:194-7.
67. Inzelberg R, Kipervasser S, Korczyn AD, Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry (1998) 64:533-5.
68. Ishii K, Yamaji S, Kitagaki H et al, Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology (1999) 53:413-16.
69. Kato K, Wada T, Kawakatsu S, Otani K, Improvement of both psychotic symptoms and Parkinsonism in a case of dementia with Lewy bodies by the combination therapy of risperidone and L-DOPA. Prog Neuropsychopharmacol Biol Psychiatry (2002) 26:201-3.
70. Kaufer DI, Catt KE, Lopez OL, DeKosky ST, Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology (1998) 51:1512.
71. Klatka LA, Louis ED, Schiffer RB, Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer’s disease and Parkinson’s disease comparison groups. Neurology (1996) 47:1148-52.
72. Kosaka K, Diffuse Lewy body disease in Japan. J Neurol (1990) 237:197-204.
73. Kovari E, Gold G, Herrmann FR et al, Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson’s disease. Acta Neuropathol (Berl) (2003) 106:83-8.
74. Lanctot KL, Herrmann N, Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry (2000)15:338-45.
75. Langlais PJ, Thai L, Hansen L et al, Neurotransmitters in basal ganglia and cortex of Alzheimer’s disease with and without Lewy bodies. Neurology (1993) 43: 1927-34.
76. Lebert F, Pasquier F, Souliez L, Petit H, Tacrine efficacy in Lewy body dementia. Int J Geriatr Psychiatry (1998) 13:516-19.
77. Lee HW, Hong SB, Seo DW et al, Mapping of functional organization in human visual cortex: electrical cortical stimulation. Neurology 2000 Feb 22; 54(4):849-54.PMID 10690975
78. Leroi I, Voulgari A, Breitner JC, Lyketsos CG, The epidemiology of psychosis in dementia. Am J Geriatr Psychiatry (2003) 11:83-91.
79. Litvan I, Maclntyre A, Goetz CG et al, Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 55:969-78.
80. Lobotesis K, Fenwick JD, Phipps A et al, Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology (2001) 56:643-9.
81. Maclean LE, Collins CC, Byrne EJ, Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. Int Psychogeriatr (2001) 13:277-88.
82. McKeith I, Fairbairn A, Perry R et al, Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ (1992a) 305:673-6.
83. McKeith IG, Perry RH, Fairbairn AF et al, Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med (1992b) 22:911-22.
84. McKeith IG, Ballard CG, Harrison RW, Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet (1995) 346:699.
85. McKeith IG, Galasko D, Kosaka K et al, Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 47:1113-24.
86. McKeith IG, O’Brien J. Dementia with Lewy bodies. Aust NZ J Psychiatry (1999) 33:800-8.
87. McKeith IG, Ballard CG, Perry RH et al, Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology (2000a) 54:1050-8.
88. McKeith IG, Grace JB, Walker Z et al, Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry (2000b) 15:387-92.
89. McKeith IG, Burn D, Spectrum of Parkinson’s disease, Parkinson’s dementia, and Lewy body dementia. Dementia (2000c) 18:865-83.
90. McKeith I, Del Ser T, Spano P et al, Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet (2000d) 356:2031-6.
91. McShane R, Gedling K, Reading M et al, Prospective study of relations between cortical Lewy bodies, poor eyesight, and hallucinations in Alzheimer’s disease. J Neurol Neurosurg Psychiatry (1995) 59:185-8.
92. McShane R, Keene J, Gedling K, Hope T, Hallucinations, cortical Lewy body pathology, cognitive function and neuroleptics use in dementia. In: Perry RH, McKeith IG, Perry EK, eds, Dementia with Lewy Bodies (1st edn) (Cambridge University Press: Cambridge, 1996) 85-98.
93. Marin RS, Differential diagnosis and classification of apathy. Am J Psychiatry (1990) 147:22-30.
94. Mesulam MM, Hersh LB, Mash DC, Geula C, Differential cholinergic innervation within functional subdivisions of the human cerebral cortex: a choline acetyltransferase study. J Comp Neurol (1992) 318:316-28.
95. Middelkoop HA, van der Flier WM, Burton EJ et al, Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology (2001) 57:2117-20.
96. Miller BL, Urrutia LE, Cornford M, Mena I, The clinical and functional imaging characteristics of parkinsonian dementia. In Perry RH, McKeith IG, Perry EK, eds, Dementia with Lewy Bodies (1st edn) (Cambridge University Press: Cambridge, UK, 1996) 114-31.
97. Minoshima S, Foster NL, Sima AA et al, Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol (2001) 50:358-65.
98. Mori E, Shimomura T, Fujimori M et al, Visuoperceptual impairment in dementia with Lewy bodies. Arch Neurol (2000) 57:489-93.
99. Morphy MA, Feldman JA, Kilburn G, Hallervorden-Spatz disease in a psychiatric setting. J Clin Psychiatry (1989) 50:66-8.
100. Oner O, Oner P, Deda G, Icagasioglu D, Psychotic disorder in a case with Hallervorden-Spatz disease. Acta Psychiatr Scand (2003)108:394-7.
101. Papka M, Rubio A, Schiffer RB, Cox C, Lewy body disease: can we diagnose it? J Neuropsychiatry Clin Neurosci (1998) 10:405-12.
102. Pasquier J, Michel BF, Brenot-Rossi I et al, Value of 99mTc-ECD SPECT for the diagnosis of dementia with Lewy bodies. Eur J Nucl Med Mol Imaging (2002) 29:1342-8.
103. Perry EK, Perry RH, Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn (1995) 28: 240-58.
104. Perry EK, Kerwin J, Perry RH et al, Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of Lewy body type. Dementia (1990a) 1:2-4.
105. Perry EK, Marshall E, Perry RH et al, Cholinergic and dopaminergic activities in senile dementia of Lewy body type. Alzheimer Dis Assoc Disord (1990b) 4:87-95.
106. Perry EK, Marshall E, Kerwin J et al, Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem (1990c) 55:1454-6.
107. Perry EK, Irving D, Kerwin JM et al, Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord (1993a) 7:69-79.
108. Perry EK, Marshall E, Thompson P et al, Monoaminergic activities in Lewy body dementia: relation to hallucinosis and extrapyramidal features. J Neural Transm Park Dis Dement Sect (1993b) 6:167-77.
109. Perry EK, Haroutunian V, Davis KL et al, Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer’s disease. Neuroreport (1994) 5:747-9.
110. Perry RH, Irving D, Blessed G et al, Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sei (1990) 95:119-39.
111. Piggott MA, Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution. Brain (1999) 122:1449-68.
112. Pilo L, Ring H, Quinn N, Trimble M, Depression in multiple system atrophy and in idiopathic Parkinson’s disease: a pilot comparative study. Biol Psychiatry (1996) 39:803-7.
113. Querfurth HW, Allam GJ, Geffroy MA et al, Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial. Dement Geriatr Cogn Disord (2000) 11:314-21.
114. Rockwell E, Choure J, Galasko D et al, Psychopathology at initial diagnosis in dementia with Lewy bodies versus Alzheimer disease: comparison of matched groups with autopsy-confirmed diagnoses. Int J Geriatr Psychiatry (2000) 15:819-23.
115. Rosen J, Zubenko GS, Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer’s disease. Biol Psychiatry (1991) 29: 224-32.
116. Sachs OW, Aguilar MJ, Brown MJ, Hallervorden-Spatz disease: its pathogenesis and place among the axonal dystrophies. Acta Neuropathologica (1966) 6:164-74.
117. Salmon DP, Galasko D, Neuropsychological aspects of Lewy body dementia. In: Perry RH, McKeith IG, Perry EK, eds, Dementia with Lewy Bodies (1st edn) (Cambridge University Press: Cambridge, 1996) 99-113.
118. Samuel W, Caligiuri M, Galasko D et al, Better cognitive and Psychopathologie response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry (2000) 15: 794-802.
119. Sanchez-Ramos JR, Ortoll R, Paulson GW, Visual hallucinations associated with Parkinson disease. Arch Neurol (1996) 53:1265-8.
120. Shea C, MacKnight C, Rockwood K, Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr (1998) 10: 229-38.
121. Simard M, van Reekum R, Cohen T, A review of the cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci (2000) 12:425-50.
122. Spigset O, Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf (1999) 20:277-87.
123. Steele C, Rovner B, Chase GA, Folstein M, Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry (1990) 147: 1049-51.
124. Swanberg MM, Cummings JL, Benefit-risk considerations in the treatment of dementia with Lewy bodies. Drug Saf (2002) 25:511-23.
125. Sweet RA, Hamilton RL, Healy MT et al, Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol (2001) 58:466-72.
126. Takahashi H, Yoshida K, Sugita T et al, Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry (2003) 27:549-53.
127. Teunisse RJ, Cruysberg JR, Hoefnagels WH et al, Visual hallucinations in psychologically normal people: Charles Bonnet’s syndrome. Lancet (1996) 347:794-7.
128. Tiraboschi P, Hansen LA, Alford M et al, Cholinergic dysfunction in diseases with Lewy bodies. Neurology (2000) 54:407-11.
129. Walker Z, Grace J, Overshot R et al, Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry (1999) 14:459-66.
130. Weiner MF, Risser RC, Cullum CM et al, Alzheimer’s disease and its Lewy body variant: a clinical analysis of postmortem verified cases. Am J Psychiatry (1996) 153:1269-73.
131. Wigboldus JM, Bryun GW, Hallervorden-Spatz disease. In: Vinken PJ, Bryun GW eds, Handbook of Clinical Neurology Diseases of the Basal Ganglia (Elsevier: Amsterdam, 1968) Vol. 6, 604-31.
132. Yudofsky SC, Hales RE eds, American Psychiatric Press Textbook of Neuropsychiatry (2nd edn) (American Psychiatric Press: Arlington, 1992).